Faron reports positive headline data from FPCLI001 clinical study with FP- 1201 in acute lung injuries

Faron Pharmaceuticals Ltd. ("Faron") announced today that it has obtained positive headline data from the Phase II part of the clinical study FPCLI001. These data indicate that the use of the FP-1201 dose regimen (six daily doses of 10 microgram/day) in acute lung injury (ALI) and its more severe form Acute Respiratory Distress Syndrome (ARDS)

  • was well tolerated
  • significantly reduced the all cause mortality in patients at day 28

pdf Download press release